Table 1.
In vitro inhibitory effects of compounds 3a–d, 4a–m and CA4 against the proliferation of murine leukemia (L1210), murine mammary carcinoma (FM3A), human T-lymphocyte (Molt/4 and CEM) and human cervix carcinoma (HeLa) cells
| Compound | IC50a (nM) | ||||
|---|---|---|---|---|---|
| L1210 | FM3A/0 | Molt4/C8 | CEM/0 | Hela | |
| 3a | >10,000 | >10,000 | >10,000 | >10,000 | n.d. |
| 3b | >10,000 | >10,000 | >10,000 | >10,000 | n.d. |
| 3c | 39 ± 16 | 46 ± 12 | 10 ± 7 | 7.7 ±2.9 | n.d. |
| 3d | 33 ± 29 | 27 ± 13 | 8.5 ± 1.4 | 8.9 ±2.0 | n.d. |
| 4a | 490 ± 40 | 860 ± 16 | 500 ± 31 | 510 ± 17 | 1100 ± 100 |
| 4b | 87 ± 5 | 99 ± 0 | 75 ± 6 | 83 ± 9 | 75 ± 5 |
| 4c | 580 ± 15 | 790 ± 18 | 2100 ± 300 | 3000 ± 100 | 900 ± 23 |
| 4d | 1200 ± 200 | 1500 ± 0 | 550 ± 14 | 1700 ± 40 | 590 ± 32 |
| 4e | 84 ± 5 | 85 ± 4 | 27 ± 2 | 46 ± 7 | 24 ± 1 |
| 4f | 140 ± 20 | 190 ± 30 | 93 ± 5 | 94 ± 5 | 99 ± 1 |
| 4g | 19 ± 2 | 23 ± 7 | 18 ± 0 | 19 ± 1 | 16 ± 1 |
| 4h | 600 ± 10 | 550 ± 10 | 430 ± 10 | 500 ± 50 | 460 ± 10 |
| 4i | 30 ± 2 | 45 ± 2 | 18 ± 0 | 19 ± 1 | 18 ± 2 |
| 4j | 25 ± 4 | 35 ± 4 | 28 ± 2 | 18 ± 4 | 21 ± 1 |
| 4k | 1100 ± 60 | 980 ± 53 | 440 ± 14 | 350 ± 15 | 220 ± 16 |
| 4l | 100 ± 0 | 130 ± 10 | 56 ± 2 | 56 ± 3 | 140 ± 24 |
| 4m | 130 ± 20 | 140 ± 9 | 94 ± 8 | 110 ± 10 | 110 ± 13 |
| CA4 | 2.8 ± 1.1 | 42 ± 6.0 | 16 ± 1.4 | 1.9 ± 1.6 | 1.9 ± 1.6 |
n.d. = not determined.
a
IC50= compound concentration required to inhibit tumor cell proliferation by 50%. Data are expressed as the mean ± SE from the dose–response curves of at least three independent experiments.